Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis

Bonnot, Pierre‐Emmanuel; Piessen, Guillaume; Képénékian, Vahan; Decullier, Évelyne; Pocard, Marc; Meunier, Bernard; Béréder, Jean-Marc; Abboud, K.; Marchal, Frédéric; Quénet, F.; Goèré, Diane; Msika, Simon; Arvieux, C.; Pirró, N.; Wernert, Romuald; Rat, Patrick; Gagnière, Johan; H. Lefèvre, Jérémie; Courvoisier, Thomas; Kianmanesh, Réza; Vaudoyer, Delphine; Rivoire, Michel; Méeus, Pierre; Passot, Guillaume; Gléhen, Olivier; behalf of the FREGAT and BIG-RENAPE Networks, on

doi:10.1200/jco.18.01688

Public

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis

Published in Journal of Clinical Oncology • May 14, 2019

Authors:

Pierre‐Emmanuel Bonnot

Guillaume Piessen

Vahan Képénékian

Abstract

PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to compare outcomes between CRS-HIPEC versus CRS...

Subject

Medicine

Cytoreductive surgery

Intraperitoneal chemotherapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!